---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-24-000010"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:25:41.600357+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B

## Summary
- Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).
- FY24 guidance: Portfolio Receipts $2.6B-$2.7B, implying royalty receipts growth of 5-9% YoY.
- Announced new transactions up to $4.0B in 2023; capital deployed $2.2B in 2023.
- Repurchased ~10M shares for $305M in 2023 under $1B buyback program.
- Positive clinical updates: aficamten Ph3 success, BMS to acquire Karuna, Novartis to acquire MorphoSys.

## SEC filing metadata
- accession: 0001802768-24-000010
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/0001802768-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/rprx-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-24-000010
- JSON: https://secwatch.observer/filing/0001802768-24-000010.json
- Plain text: https://secwatch.observer/filing/0001802768-24-000010.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the fourth quarter and full year of 2023 guidance (initiated).
  - Period: the fourth quarter and full year of 2023
  - Guidance: initiated
  - Result: reported results
  source text: On February 15, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/0001802768-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.